J Bone Miner Res. 2015 May;30(5):934-44. doi: 10.1002/jbmr.2442. The results suggest almost all patients who have received six annual ZOL infusions can stop medication for up to 3 years with apparent maintenance of benefits. Autor: … Leer más
In postmenopausal women, bisphosphonates have not been shown to better decrease risk of first fracture compared with calcium and vitamin D therapy alone.
Osteoporos Int 19 may 2015 on line. DOI 10.1007/s00198-015-3168-0 PPI use was associated with fracture in young adults, but overall evidence did not support a PPI-fracture relationship in children. Young adults who use PPIs should … Leer más
Osteoporos Int 19 May online 2015. DOI 10.1007/s00198-015-3160-8 Postmenopausal women aged 50 years and older with a recent DRF had lower bone and muscle strength in both the upper and lower extremities com- pared to … Leer más
COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.
JAMA Intern Med. Published online April 13, 2015. doi:10.1001/jamainternmed.2015.0747. In this group of frail elderly women with osteoporosis, 1 dose of zoledronic acid improved BMD over 2 years. The clinical importance of nonsignificant increases in … Leer más
JAMA Intern Med. Published online April 13, 2015. doi:10.1001/jamainternmed.2015.0757 In this issue of JAMA Internal Medicine, Greenspan and colleagues1 present intriguing data on zoledronic acid, one of the most potent drugs in the bisphosphonate family—if … Leer más
J Clin Endocrinol Metab. 2015 Apr;100(4):1343-9. doi: 10.1210/jc.2014-4166. Epub 2015 Feb 2. Arterialized plasma HCO3 was associated positively with cross-sectional BMD and inversely with the rate of bone loss, implying that systemic acid-base status is … Leer más
J Clin Endocrinol Metab. 2015 Apr;100(4):1237-40. doi: 10.1210/jc.2015-1396 Autor: Magge SN.
J Clin Invest. 2015 Apr;125(4):1509-22. doi: 10.1172/JCI77716. Epub 2015 Mar 9. Together, our results indicate that miR-188 is a key regulator of the age-related switch between osteogenesis and adipogenesis of BMSCs and may represent a … Leer más
